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EMTThe cardiac valves are targets of both congenital and acquired diseases. The formation of valves during embryo-
genesis (i.e., valvulogenesis) originates from endocardial cells lining themyocardium. These cells undergo an en-
dothelial–mesenchymal transition, proliferate and migrate within an extracellular matrix. This leads to the
formation of bilateral cardiac cushions in both the atrioventricular canal and the outﬂow tract. The embryonic
origin of both the endocardium and prospective valve cells is still elusive. Endocardial and myocardial lineages
are segregated early during embryogenesis and such a cell fate decision can be recapitulated in vitro by embry-
onic stem cells (ESC). Besides geneticallymodiﬁedmice and ex vivo heart explants, ESCs provide a cellularmodel
to study the early steps of valve development and might constitute a human therapeutic cell source for
decellularized tissue-engineered valves. This article is part of a Special Issue entitled: Cardiomyocyte Biology:
Cardiac Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The heart functions by pumping out oxygenated blood to the body
through the aortic valve and the aorta, and deoxygenated blood to the
lungs through the pulmonary valve and artery. During the cardiac
cycle, blood originating from the lung is pumped via the pulmonary
vein into the left atria and then into the left ventricle through the mi-
tral valve. Similarly, deoxygenated blood is pumped via the vena cava
into the right atria and ﬂows through the tricuspid valve to reach the
right ventricle.
The architecture of both the semilunar valves (aortic and pulmonary
valves) and the atrioventricular valves (tricuspid or mitral valves) al-
lows for unidirectional opening and, in turn, blood ﬂow. The valves fea-
ture two leaﬂets or cusps that allow for their opening and closure. The
opening is surrounded by a ﬁbrous ring or annulus ﬁbrosus. The leaﬂets
are prevented from prolapsing into thewrong direction by the action of
chordae tendineae. The chordae tendinae are tendon chords linking the
papillary muscles to the tricuspid valve in the right ventricle and the
mitral valve in the left ventricle. They are attached to the posterior
spongious region of the valve [1,2] (Fig. 1).
The structure of the valve (Fig. 1) is the result of complex develop-
mental events including speciﬁcation and determination of cell line-
ages, endothelial to mesenchymal transition (EMT) of endocardial
cells and cell migration, as well as morphogenetic and biomechanical
(shear stress) phenomena [3].diomyocyte Biology: Cardiac
ction.
rights reserved.Cardiac valves form between E9.5 (cushion formation) and E14.5
(maturation of leaﬂets) and are then functional in the mouse embryo
as recorded by Doppler echocardiography (Fig. 2) which reveals uni-
directional blood ﬂow. In humans, valves are formed between the 5th
and the 8th weeks of fetal life. Valves are affected in up to one third of
cardiac congenital pathologies [4]. The valves open more than 2.5 bil-
lion times in the life of an adult individual. This subjects the thin valve
leaﬂets to high mechanical strains which ultimately lead to aging of
the tissue, a physiological event often exacerbated by pathologies
which primarily affect the myocardium. In adults, the prevalence of
valvular heart diseases increases dramatically with age reaching 13%
of patients who are 75 years old and older [5–7].
One of the therapeutic solutions to circumvent a valvular dysfunc-
tion is the replacement of the valve by a prosthetic device [8]. Howev-
er, these prosthetic valves neither grow nor remodel. This approach is
thus limiting in children undergoing a surgery at birth while their
bodies will further grow. Engineered materials that promote native
developmental biology cues and signaling are currently under inves-
tigation to providemechanical integrity and plasticity once implanted
[9]. Alternatively, cell therapy (i.e., bringing new cells including en-
dothelial cells or valvular ﬁbroblasts) has also been proposed in com-
bination to valve bioengineering to repair myxomatous valves [10].
Such a therapeutic approach ideally requires the generation of the ap-
propriate human cell type, and thus a better understanding of the de-
velopmental pathways governing the formation of both embryonic
and mature valves.
The ﬁrst steps of valvulogenesis take place in the atrio-ventricular
canal (AVC) and the outﬂow tract (OFT). The AVC and OFT develop
when the heart tube elongates and then loops, forming the primary
spongious
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Fig. 1. Two perspectives of the atrioventricular valve structure. Component of a mature
valve including the ﬁbrosa (dense collagen), spongiosa (enriched in proteoglycan and
glycosaminoglycan) and the atrialis or the ventricularis including smooth muscle cells
in atrialis and valve endothelial cells in both (loose ﬁbroelastic structure). The chordae
tendinae links the leaﬂet with the papillary muscle.
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Fig. 3. Transcriptional pathways underlying the process of EMT and formation of cardiac
cushion. Myocardial BMP works together with Notch and TGFb on endocardial cells to
induce their EMT. The endocardium-derived cells, VIC express a speciﬁc set of genes
that includes Twist, Tbx20, Soxs, andMsxs. VIC: valve interstitial cell.
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from themyocardium by a space ﬁlled by an extracellular matrix (ECM),
or cardiac jelly, mainly composed of hyaluronan and chondroitin sulfates
[11]. The myocardium also secretes ECM at discrete locations of the AVC
and OFT. Endocardial cells located in the neighborhood respond to local
signals including BMP2, TGFβ and notch signaling pathways, delaminate
and migrate while undergoing EMT. Post-EMT VIC cells express among
other genes, Sox9, Sox5, Sox6, Msxs, Tbx20, Twist and Snail and Slug. This
process leads to the formation of the cardiac cushions [4,11,12] (Fig. 3).
Various cardiac embryonic lineages contribute to the early steps of
valvulogenesis which is still a poorly understood developmental pro-
cess [4,13]. Chicken and mouse embryos have provided some cues to
this process. Embryonic stem cells originating from the blastocyst re-
capitulate many early developmental events including the formation
of endocardial cells [14]. Directed differentiation of these cells might also
bring useful information in order to better comprehend the ﬁrst steps of
valvulogenesis.
This overview updates the origin of cell lineages which contribute
to the endocardium, the signaling (both biological and mechanical)
pathways which play a role in the determination of these lineages
as well as the formation of the cardiac cushions. I will further discuss
how human embryonic stem cells contribute to a better understand-
ing of the developmental biology of valves and provide potential ther-
apeutic cells for myxomatous valves.1.1. Embryological origin of the endocardium
Endocardial cells are endothelial cells that form the inner layer of the
heart in continuitywith the endotheliumof the vessels. The endocardial20 deg
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Fig. 2. Continuous wave Doppler recording of the blood ﬂow through the aortic valve in
E14.5 embryo in utero.layer appears very early during evolution in the Agnathans ( lamprey)
[15] and correlates with the formation of a valve between the two car-
diac chambers providing a unidirectional blood ﬂow [16].
Surprisingly, despite these evo-devo data and early focused devel-
opmental biology studies in the 1960s, the embryonic origin of the
endocardium has not yet been fully elucidated [17]. Pioneer studies
in the chicken and quail embryos fromMikawa's and Markwald's lab-
oratories have strongly suggested an early segregation of endocardial
and myocardial progenitors prior to or at the onset of gastrulation.
Using a cell lineage tracing with a retroviral vector encoding a gene
reporter to infect cells in the rostral portion of HH stage 3 chick prim-
itive streak (PS), Mikawa's laboratory observed that a speciﬁc region
of the PS generates a daughter population thatmigrates into the bilateral
heart regions, and differentiates into either endocardial or myocardial
cells. No cells remain bipotent at this PS stage [18,19]. These ﬁndings
argue against a common progenitor betweenmyocardial and endocardi-
al cells at this stage of development. In the quail, using labeling against
the endothelial marker QH-1, Sugi and collaborators identiﬁed an endo-
cardial endothelial cell population in the precardiac mesoderm from
stage 5 embryos [20]. Determination of endocardial cell fate thus occurs
before the formation of the primary heart ﬁeld.
In the mouse, endocardial cells are ﬁrst detected at E7.5 as a sub-
population of mesodermal cardiogenic cells that down-regulate
N-cadherin [21]. Genetic lineage tracing studies in the mouse [22]
reported that a Flk1+ progenitor emerges when epiblast cells exit the
PS and differentiate into, besides other mesodermal derivatives, both
endocardial and some myocardial cells. Thus, endocardial and myocar-
dial cells are already determined when they together form the primary
heart ﬁeld in the mouse embryo.
Besides the early segregation of endocardial cells amongmesodermal
cells, Isl1Cre labeled cells [23,24] and Mef2c-AHF-Cre labeled cells [25]
were also shown to give rise to both the myocardium and the endocar-
dium. Thus, the cells of the second heart ﬁeld (i.e., Flk1-cells) contribute
at least partially to the formation of the endocardium by re-expressing
Flk1 before reaching the endothelial layer.
In the cardiac crescent, the Ets-family protein Etv2 has been iden-
tiﬁed as an Nkx2-5 target and a key gene for endothelial–endocardial
speciﬁcation [26], conﬁrming that endocardial cells arise from a de
novo process of vasculogenesis. In a recent paper [13], the authors
used a live imaging approach in quail embryos and lineage tracing
in mouse. They found that the endocardium derives from a vascular
endothelial lineage as also suggested by Rasmussen et al. [27]. Flk1+
mesodermal cells are thus a key cell population in forming the endo-
cardium. However, this layer originates from both an early Flk1+/Isl1-
and a late sub-set of Flk1-/Isl1+ lineages, pointing to two embryonic
origins for these cells [13] (Fig. 4). Nevertheless, the exact timing of
segregation of endocardial and myocardial lineages in both bilateral
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the second heart ﬁeld is still unknown.
The extracellularmatrix (ECM) contributes to the cell determination
process and setting of the endocardial cells lining the myocardium. The
endocardial progenitors move early into an ECM-rich environment lo-
cated between the splanchnic mesoderm and the endoderm. This
ECM includes collagen I and IV, ﬁbronectin, laminin and ﬁbrilllins 1
and 2. Later, the endocardial and myocardial cells of the primary heart
ﬁeld forming the cardiac crescent, will build up the cardiac tube while
remaining separated from each other by an acellular ECM or cardiac
jelly [12,28]. Several cell types contribute to the formation of the cardiac
jelly. These include early endodermal and lateral platemesodermal cells
and myocardial cells [29,30].
Both ﬁbronectin and ﬁbrillin-2 bind morphogens such as TGFβ [31]
and VEGF [32], suggesting a potential role of the matrix and jelly in de-
termining cell fate and proliferation as well as, later on, in themodeling
of the cardiac cushions.
Besides the early determination of the endocardium-derived val-
vular cells, a late contribution of epicardium-derived cells to the for-
mation of the leaﬂets of semilunar valves has been reported [33,34]
in chicken embryo. This epicardial contribution to the valves was re-
cently conﬁrmed in the mouse embryo [35] (Fig. 4). Cells migrating
from the cardiac neural crest also speciﬁcally participate in the forma-
tion of semilunar valves [36].
Further experiments using an alternative approach are required to
fully delineate the cell lineages contributing to the endocardial layer.
A retrospective clonal analysis using LaacZ embryos [37,38] should
shed light on this issue.
1.2. EMT of endocardial cells and formation of cardiac cushions
EMT is an ancient biological process which is characterized by a loss
of cell adhesion proteins and adherent junctions of epithelial cells that
acquire the morphology of mesenchymal cells [39]. Both cardiac pro-
genitors and more differentiated cells result from several processes
of EMT that occur during their embryonic life. Epiblast cells ﬁrst con-
vert into mesenchymal cells forming part of the lateral plate meso-
derm (LPM) at the origin of the ﬁrst prospective cardiac cells. The
LPM forms two new epithelial cell sheets, i.e. the somatopleure andEPDC
ES cells
Blastocyst
Late Streak
     stage
Ectoderm
FHL
SHL
Me
Nkx
Tb
PA
D
Pr
Endocardial 
progenitor
Flk1
Flk1
high
low
GATA5,Cx37,NFATc,Tbx20, Etv2,N1lCD
Smad6, Isl1, VE-cadherin, CD31, Tie
Wt1+, Tbx18+
LPM
CCM
En
do
de
rm
    Extra
Embryonic
PM
Me
sP
1
CC
HF
ICM
Em
br
yo
ni
c
Fig. 4. Cell lineages contributing to the formation of the endocardium and valves. Endocardia
second heart ﬁeld. Both progenitors participate in the formation of the leaﬂets. Epicardium d
a later stage. CC: cardiac crescent; CCM: cranial cardiac mesoderm; EPDC: epicardium derive
mesoderm; VEC: valve endothelial cell progenitor; VIC: valve interstitial cell.splanchnopleure under the control of the ectoderm [40]. The
splanchnopleure undergoes a second EMT to form the splanchnic
mesoderm at the origin of both myocardial (ﬁrst heart ﬁeld) and en-
docardial cells.
Endocardial endothelial valve prospective cells (VEC) undergo a
third EMT under the action of BMP2 in the AVC or of BMP4 in the
OFT, both secreted by the myocardium, in order to form the cardiac
cushions. A BMP signaling pathway in the endocardium is activated
through ALK3 and ALK6 and regulates, through a Notch-dependent
pathway, downstream TGFβ2 secretion which also participates in the
initiation of EMT (Table 1; Fig. 3; for review: [41,42]). Indeed, TGFβ2
knock-out mice, but not TGFβ1 or TGFβ3 knock-out mice, feature a de-
ﬁcient EMT in the cardiac cushions [43] (Table 1). Tbx2, speciﬁcally
expressed under the tight regulation of BMP2 in both the myocardium
and the endocardium of the AVC, prevents expression of cardiac cham-
ber genes [44] as well as EMT within the ventricular region [45]. This
gene has been expressed early in the evolution. The lamprey, the ﬁrst
organism to develop an endocardial layer as well as cardiac valves, ex-
presses LjTbx2/3A in the non-chambered myocardium, supporting the
idea that acquisition of Tbx2/3 expression may have allowed primitive
tubular hearts to partition, giving rise to multi-chambered hearts and
in turn the necessary valves [46].
The VIC (ﬁbroblasts) generated by the EMTprocess invade the cardi-
ac jelly, proliferate under the action of VEGF and form the cushions. A
few genes including Twist, Tbx20, and Sox9 and their downstream tar-
gets Sox5 and Sox6 are instrumental to regulate this proliferative stage
(Fig. 3).
Periostin, a fascilin domain including protein, is expressed in the car-
diac mesenchyme of the cushions. The periostin knock-out mouse fea-
tures shortened and thicker valve leaﬂets, revealing a role of periostin
in the differentiation of mesenchymal cushions (for review [47]).
A series of transgenic mouse lines generated in the last decade dis-
play deﬁcient cardiac cushions or, for a minority of them, cushion en-
largement due to dysregulation of EMT (Table 1). These mice led to
the identiﬁcation of transcriptional and signaling pathways involved
in EMT of speciﬁc endocardial cells.
While we now better understand the EMT process thanks to the
3D collagen hydrogel ex-vivo approach [48] and this series of trans-
genic mice (Table 1), the remaining question is why only a subset of   aortic
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Table 1
Genes and signaling pathways involved in the formation of cardiac cushions.
Genes/signaling pathways EMT cardiac cushions References
Smad4 deﬁcient [70,71]
Gata4 deﬁcient [72]
Smad7 deﬁcient [70]
Cpsg2 deﬁcient [73]
RPP-J (Notch) deﬁcient [74]
ALK2, ALK3, BMP-2,
(redundant roles of BMP-4, -5, -6, -7)
deﬁcient [75–79]
For recent
review: [80]
TGFbRII deﬁcient [81]
Cx40 deﬁcient [82]
Cx45 deﬁcient [83]
CHF1/Hey1 deﬁcient [84]
Trisomy 16 deﬁcient [85]
Adm19 deﬁcient [86]
SHP2 Noonan Enlarged cushion [87]
Tbx20 deﬁcient [88]
Endoglin deﬁcient [89]
twist deﬁcient [88,90]
Sox9 deﬁcient [91]
PDK1 deﬁcient [92]
Fog2 Enlarged cushion [93]
Ezh2 deﬁcient [54]
Mmp15 snail deﬁcient [94]
Msx1/2 deﬁcient [95]
Smad6 deﬁcient [96]
Slug deﬁcient [97]
Irx3,5 deﬁcient [98]
RA deﬁcient [99–102]
Tbx2(misexpression in myocardium) Excess EMT [45]
MAPK pathway MEKK4 deﬁcient [103]
Versican deﬁcient [73]
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ions. Several lines of research are emerging to address this question.
Pioneering work in zebraﬁsh reported the role of micro RNAs in the
formation of ECM. Mir23 targets hyaluronic acid synthase 2(Has2),
Icat, and Tmem2, thus restricting cushion formation [49]. The involve-
ment ofmiRs to locally restrict gene expression and in turn the EMT pro-
cess is appealing. Investigation in the mouse embryo will further tell us
whether such amiR-dependent process is conserved inmammals. Then
the chicken or egg question emerges: how a localized Mir expression
can be explained? What are the upstream morphogens which regulate
miRs in this region?
A possible gradient of expression of BMP2 or smad in this region
could also explain a local high activity of this transduction pathway and
a possible expression of a reprogrammation factor at the origin of EMT.
Biomechanical events have also been reported to contribute to the
localized EMT process. Indeed an elegant paper recently reported that
endocardial cells harbor a cilia; such a structure translates local blood
ﬂow signal into functional responses, including nitric oxide production
likely produced by the ciliated cells [50] as an important cue for valve
formation and initiation of gene expression. However cells, submitted
to constant high ﬂow, loose their cilia, down-regulate Klf4, stop Klf2
up-regulation, and undergo EMT in a TGFβ-dependent manner [51].
The role of mechanobiology in the process of EMT of the cardiac cush-
ions is just emerging. This question is expected to be more thoroughly
investigated in the near future [52,53].
Epigenetic events which occur throughout the genome at the re-
gions of speciﬁc gene enhancers are likely to regulate gene expression
in cardiac cushions [54] in a space-restricted manner and in speciﬁc
cells prone to undergo EMT. EMT is indeed associated with cell
reprogrammation regulated by epigenetic events [55,56]. Immuno-
precipitation of chromatin of AVC cells combined to deep sequencing
assays using antibodies directed against markers of active epigenetic
events at enhancers (anti-modiﬁed histones H3K4m1, anti-p300 …)
should identify enhancers and possibly genes that are instrumental
in AVC cells before or at the onset of EMT ( E9.5 in mouse embryo).Following EMT of cardiac cushions, developing valves are com-
posed of multiple cell types, including a subset of them that express
the transcription factor scleraxis (scx) and other tendon-associated
structural proteins. Scx expression is further correlated with sox9
downregulation. These genes are under the regulation of FGF4/Erk
(scx) or BMP/Smad (sox9, agregan …) signaling pathways [57].Thus,
EMT does not engage all endocardial cells to the same phenotype. A
tight balance between BMP and FGF signaling pathways is set during
EMT to drive the cells to chondrogenic or tendinous phenotype en-
suring a proper distribution of various cell types that are required to
optimal valve function. Such a subtle balance of signaling pathways
remains to be better deﬁned in a space- and temporal-manner using
in-vivo, ex-vivo and in-vitro experimental settings.
1.3. Embryonic stem cells recapitulate early valvulogenesis and provide
potential therapeutic cells
While transgenic mice have provided us with invaluable informa-
tion as to the role of speciﬁc genes, or signaling pathways regulating
valve formation, the knowledge of early human processes of
valvulogenesis is still limited. Furthermore, the ﬁrst steps of the later
process (i.e., cell lineage speciﬁcation, triggering signals of EMT in cush-
ion formation) are still very elusive both in the mouse and human em-
bryos. Thus, embryonic stem cells bring a cellular model to investigate
such events.
We have derived a population of MesP1+ cells from human em-
bryonic stem cells (HUESC) [58]. This cell population is obtained by
a combination of BMP2 and secreted Wnt3a [59,60]. Guided by the
developmental biology approach, this population is further chal-
lenged by FGF8 to direct their fate toward the second heart lineage
and VEGF to favor the endothelial phenotype [59]. Using some stro-
mal factors of the ECM of embryonic ﬁbroblasts, MesP1+ cells acquire
the phenotype of valve endocardial cells (VEC) expressing the proteins
CD31, Isl1, Tbx20, VEcadherin, Smad6, Msx1 and NFATc. The HUESC-
derived cells further undergo EMT under different experimental condi-
tions including high BMP2 treatment, co-culture on AVC mouse explants
seeded on collagen gels or injection into the AVC of E10.5mouse embryos
(Neri et al. in revision; [61]). Thus HUESCs, as mouse ESCs [14], recapitu-
late the formation of the endocardium and further early valvulogenesis.
This cell population is very promising from several points of views:
The cells do recapitulate step by step the different lineages that
contribute to the endocardium which makes them a faithful model
to study the cell fate decisions and the EMT process in a human con-
text including the processes of mechanobiology.
Several options emerge in cell therapy of valve disease. The cells
might be used to restore a population of quiescent ﬁbroblasts (VIC)
in congenital valve disease with improper valve formation or in a
degenerating leaﬂet of an aging valve. Such an approach could de-
crease the stiffness of the leaﬂet induced by an increased number in
myoﬁbroblasts [62]. Such a restoration of the leaﬂet could be accom-
panied by a drug and/or growth factor delivery to ensure a better
maturation of the cells, for example, toward a tendinous (using FGF
and BMP inhibitors) or more chondrogenic (using BMP2 and FGF in-
hibitors) cell fate. Addition of exogenous cells could also mobilize en-
dogenous cells such as endothelial progenitors from the circulation
acting through secreted and chemoattractant factors.
Alternatively, HUESC-derived VICs could be used to repopulate a
decellularized valve in order to build up a suitable biological valve
scaffold that could be more adapted in mitral stenosis or aortic valve
disease to replace calciﬁed valves [10].
Indeed the decellularization approach has been applied to valves to
test tissue-engineering of valve replacements [63]. The idea to repopulate
the decellularized valve has thus been tested in a few laboratories andhas
proven to be feasible in a prospective clinical arena [64,65] using human
valves [66]. This process overcomes the limitations of prosthetic valves,
(i.e., lack of growth, repair and of remodeling) and could match with
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best prosthetic valve [67]. The main issue in this therapeutic approach
is to ﬁnd the right cell population to repopulate the decellularized
valve. Many cells, including endothelial or hematopoietic cells, have
been tested [68,69] with limited success. A genuine population of
human VICs is expected to better fulﬁll the role of original valvular
cells and might have an additional repair beneﬁt. Human ES and iPS
cells and their valvular derivatives might provide new strategies in
this ﬁeld of developmental biology research and medical applications.
Valvulogenesis is a complex developmental process including ge-
netic, epigenetic, morphogenetic and mechanical events that remain
to be better understood. Using the combination of mouse transgenic
embryos, ex vivo AVC and OFT explants and pluripotent stem cells, we
are in a position to better document this developmental biology ﬁeld
for the beneﬁt of a better understanding and cure (treatment) of con-
genital and acquired valvulopathies.
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